Abstract #844: Can B-Lymphocyte Stimulator (BLYS) be a Serological Prognostic Marker in Patients with Neuroendocrine Tumors?

MLA

Elio Tonutti, et al. “Abstract #844: Can B-Lymphocyte Stimulator (BLYS) Be a Serological Prognostic Marker in Patients with Neuroendocrine Tumors?” Endocrine Practice, vol. 22, May 2016, pp. 184–85. EBSCOhost, https://doi.org/10.1016/s1530-891x(20)45178-x.

APA

Elio Tonutti, Franco Grimaldi, Cinzia Pistis, Martina Fabris, Veronica Tonelli, Francesco Curcio, Fabio Vescini, Cecilia Motta, & Claudia Cipri. (2016). Abstract #844: Can B-Lymphocyte Stimulator (BLYS) be a Serological Prognostic Marker in Patients with Neuroendocrine Tumors? Endocrine Practice, 22, 184–185. https://doi.org/10.1016/s1530-891x(20)45178-x

Chicago

Elio Tonutti, Franco Grimaldi, Cinzia Pistis, Martina Fabris, Veronica Tonelli, Francesco Curcio, Fabio Vescini, Cecilia Motta, and Claudia Cipri. 2016. “Abstract #844: Can B-Lymphocyte Stimulator (BLYS) Be a Serological Prognostic Marker in Patients with Neuroendocrine Tumors?” Endocrine Practice 22 (May): 184–85. doi:10.1016/s1530-891x(20)45178-x.